All News
Filter News
Found 183 articles
-
Exscientia continues expansion with establishment of a subsidiary in Japan to target the pharmaceutical market across Asia
3/22/2019
Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company announces the establishment of a subsidiary, Exscientia K.K to spearhead its pharmaceutical interests across Asia.
-
Exscientia will use its full-stack AI drug discovery platform, Centaur Chemist, to accelerate the discovery of small molecule therapeutic drug candidates. It will focus on three of Celgene’s therapeutic programs in oncology and autoimmunity.
-
Exscientia hires Director of Data Engineering to scale up its AI drug discovery platform
2/13/2019
Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia is pleased to welcome Andrew Douglas as the new Director of Data Engineering.
-
EVOTEC INVESTS IN FINANCING ROUND OF EXSCIENTIA
1/7/2019
$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC
-
Portfolio news - Exscientia raises US$26 million in Series B funding round and announces AI drug discovery collaboration with Roche worth up to CHF 67 million
1/7/2019
The Company has raised US$26 million in a Series B financing round to scale up its pipeline and advance selected programmes towards clinical development.
-
Technology is constantly impacting and changing the way the world works. Greater technological innovations are not only changing the way business operate, but also have significant impact on employees.
-
The UK’s first dedicated Vaccines Manufacturing Innovation Centre to be located at The Oxford Science Park
12/3/2018
Facility to cement Park’s position in UK life sciences ecosystem
-
Exscientia Builds “Full Stack” AI-driven Drug Discovery Capabilities through Acquisition of Kinetic Discovery
11/15/2018
Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.
-
Leading AI-driven drug discovery company Exscientia expands to The Oxford Science Park
11/1/2018
Facilities in The Schrödinger Building to bring together AI experts and biologists
-
Exscientia appoints Georgy Egorov as Chief Financial Officer bringing significant capital markets and strategic development expertise to support business growth
10/3/2018
Exscientia is pleased to announce the appointment of Mr Georgy Egorov as Chief Financial Officer (CFO) effective immediately.
-
Prime Minister Theresa May continues to push for growth in the United Kingdom’s pharma sector. Today she called for expanding the role of artificial intelligence in the diagnosis process for cancer.
-
The use of artificial intelligence and machine learning in drug development has been ramping up and investors are taking keen notice of the growing trend. This morning BenevolentAI snagged $115 million.
-
Evotec AG Fiscal Year 2017 Results: Leading External Innovation
3/28/2018
Evotec AG reported financial results and corporate updates for the fiscal year ended 31 December 2017.
-
The latest funding round gives XtalPi $20M in the bank, which the company said makes it "one of the top-funded AI-powered biotechs."
-
Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman
12/11/2017
Exscientia, the innovative company at the forefront of AI-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman.
-
Exscientia Opens New Office in Oxford as Part of Plan for Rapid Growth and Expansion
12/4/2017
Exscientia, the leading AI-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK's most dynamic life science cluster.
-
Evotec AG Announces First Nine-Month 2017 Results and Corporate Update
11/8/2017
In the first nine months of 2017, Evotec's Group revenues grew to EUR 170.9 m, an increase of 42% compared to the same period of 2016 (9M 2016: EUR 120.6 m).
-
Salaries and total compensation can range from $300,000 to $500,000 per year for these employees – whether they have a Ph.D. or are just out of college.
-
Evotec AG Invests In Exscientia To Advance AI-Driven Drug Discovery
9/28/2017
-
GlaxoSmithKline Turns to AI to Speed Up Drug Discovery in $43 Million Deal
7/5/2017